Breast cancer: Occurrence, risk factors and hormone metabolism

Expert Review of Anticancer Therapy

Volumn 3, Issue 4, 2003, Pages 546-562

  Sasco, Annie J ^a   Kaaks, Rudolf ^a   Little, Ruth E ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Breast cancer; Environment; Epidemiology; Estrogen; Hormones; Lifestyle; Radiation; Reproduction; Sex steroids

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; INSULIN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; SEX HORMONE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; TAMOXIFEN;

AGE DISTRIBUTION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; ENDOMETRIUM CANCER; ENVIRONMENTAL EXPOSURE; FEMALE; GENE MUTATION; GENETIC RISK; GEOGRAPHIC DISTRIBUTION; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; LIFE EVENT; LIFESTYLE; MENARCHE; MENOPAUSAL SYNDROME; OCCUPATIONAL CARCINOGENESIS; RADIATION EXPOSURE; REVIEW; STEROID METABOLISM; STEROIDOGENESIS; THROMBOEMBOLISM;

EID: 0042510726     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.4.546     Document Type: Review

References (221)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2(9), 533-543 (2001).
2. Ferlay J, Bray I, Pisani P, Parkin DM. Globocan 2000 (CD-ROM). Cancer incidence, mortality and prevalence worldwide. IARC Press, Lyon, France (2001).
3. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (Eds). Breast cancer. In: Cancer incidence in five continents, volume VII. International Agency for Research on Cancer, Lyon, France, 858-859 (1997).
4. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int. J. Cancer 41(2), 184-197 (1988).
5. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J. Cancer 54(4), 594-606 (1993).
6. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80(6), 827-841 (1999).
7. Waterhouse J, Muir CS, Shanmugaratnam K, Powell J (Eds). Breast cancer. In: Cancer incidence in five continents, volume IV. International Agency for Research on Cancer, Lyon, France, 734-735 (1982).
8. Lacey JV Jr, Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ. Mol. Mutagen 39(2-3), 82-88 (2002).
9. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355(9217), 1822 (2000).
10. Ménégoz F, Chérié-Challine L. Cancer du sein. In: Le cancer en France: incidence et mortalité. Situation en 1995. Evolution entre 1975 et 1995. La documentation française, Paris, France, 76-81 (1998).
11. Berrino F, Sant M, Verdecchia A et al (Eds). Breast. In: Survival of cancer patients in Europe. The Eurocare study. IARC Scientific Publication No 132. International Agency for Research on Cancer, Lyon, France, 253-265 (1995).
12. Berrino F, Capocaccia R, Estève J et al (Eds). Breast. In: Survival of cancer patients in Europe: the Eurocare-2 study. IARC Scientific Publication No 151. International Agency for Research on Cancer, Lyon, France, 304-313 (1999).
13. Sasco AJ. Epidemiology of breast cancer: an environmental disease? APMIS 109(5), 321-332 (2001).
14. Russo J, Hu YF, Tahin Q et al. Carcinogenicity of estrogens in human breast epithelial cells. APMIS 109(1), 39-52 (2001).
15. Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J. Mammary Gland Biol. Neoplasia 3(1), 49-61 (1998).
16. Russo J, Lareef H, Tahin Q, Russo IH. Pathways of carcinogenesis and prevention in the human breast. Eur. J. Cancer 38(Suppl. 6) S31-S32 (2002).
17. Lane-Claypon JE. A further report on cancer of the breast. Reports on Public Health and Medical Subjects No. 32. His Majesty's Stationery Office, London (1926).
18. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol. Rev. 15(1), 36-47 (1993).
19. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2(3), 133-140 (2001).
20. Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur. J. Cancer Clin. Oncol. 24(1), 29-43 (1988).
21. Clavel-Chapelon F. Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br. J. Cancer 86(5), 723-727 (2002).
22. Tung HT, Tsukuma H, Tanaka H et al. Risk factors for breast cancer in Japan, with special attention to anthropometric measurements and reproductive history. Jpn. J. Clin. Oncol. 29(3), 137-146 (1999).
23. Gao YT, Shu XO, Dai Q et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int. J Cancer 87(2), 295-300 (2000).
24. Ssali JC, Gakwaya A, Katongole-Mbidde F. Risk factors for breast cancer in Ugandan women: a case-control study. East Central Afr. J. Surg. 1, 9-13 (1995).
25. Wohlfahrt J, Melbye M. Age at any birth is associated with breast cancer risk. Epidemiology 12(1), 68-73 (2001).
26. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am. J. Epidemiol. 139(8), 819-835 (1994).
27. Sanderson M, Shu XO, Jin F et al. Abortion history and breast cancer risk: results from the Shanghai Breast Cancer Study. Int. J. Cancer 92(6), 899-905 (2001).
28. Ye Z, Gao DL, Qin Q, Ray RM, Thomas DB. Breast cancer in relation to induced abortions in a cohort of Chinese women. Br. J. Cancer 87(9), 977-981 (2002).
29. Lipworth L, Bailey LR, Trichopoulos D. History of breast-feeding in relation to breast cancer risk: a review of the epidemiologic literature. J. Natl Cancer Inst. 92(4), 302-312 (2000).
30. Chang-Claude J, Eby N, Kiechle M, Bastert G, Becher H. Breastfeeding and breast cancer risk by age 50 among women in Germany. Cancer Causes Control 11(8), 687-695 (2000).
31. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet 360(9328), 187-195 (2002).
32. Zheng T, Holford TR, Mayne ST et al. Lactation and breast cancer risk: a case-control study in Connecticut. Br. J. Cancer 84(11), 1472-1476 (2001).
33. Tryggvadottir L, Tulinius H, Eyfjord JE, Sigurvinsson T. Breast cancer risk factors and age at diagnosis: an Icelandic cohort study. Int. J. Cancer 98(4), 604-608 (2002).
34. Clavel-Chapelon F, Gerber M. Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res. Treat. 72(2), 107-115 (2002).
35. Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 360(9336), 861-868 (2002).
36. World Cancer Research Fund. American Institute for Cancer Research. Food, nutrition and the prevention of cancer: a global perspective. American Institute for Cancer Research, Washington DC, USA (1997).
37. Hunter DJ, Willett WC. Nutrition and breast cancer. Cancer Causes Control 7(1), 56-68 (1996).
38. Smith-Warner SA, Spiegelman D, Adami HO et al. Types of dietary fat and breast cancer: a pooled analysis of cohort studies. Int. J. Cancer 92(5), 767-774 (2001).
39. Velie E, Kulldorff M, Schairer C et al. Dietary fat, fat subtypes and breast cancer in postmenopausal women: a prospective cohort study. J. Natl Cancer Inst. 92(10), 833-839 (2000).
40. Willett WC. Diet and cancer: one view at the start of the millennium. Cancer Epidemiol. Biomarkers Prev. 10(1), 3-8 (2001).
41. Zheng W, Gustafson DR, Sinha R et al. Well-done meat intake and the risk of breast cancer. J. Natl Cancer Inst. 90(22), 17244-1729 (1998).
42. International Agency for Research on Cancer. IARC handbooks of cancer prevention, handbook 6. Weight control and physical activity. International Agency for Research on Cancer, Lyon, France (2002).
43. Berkey CS, Frazier AL, Gardner JD, Colditz GA. Adolescence and breast carcinoma risk. Cancer 85(11), 2400-2409 (1999).
44. Barnes-Josiah D, Potter JD, Sellers TA, Himes JH. Early body size and subsequent weight gain as predictors of breast cancer incidence (Iowa, United States). Cancer Causes Control 6(2), 112-118 (1995).
45. Van Wiegen JC. Secular growth changes. In: Human growth: a comprehensive treatise, volume 3. Falkner R, Tanner JM (Eds). Plenum Press, London, UK 307-331 (1986).
46. Li CI, Malone KE, White E, Daling JR. Age when maximum height is reached as a risk factor for breast cancer among young US women. Epidemiology 8(5), 559-565 (1997).
47. Singletary KW, Gapstur SM. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms. JAMA 286(17), 2143-2151 (2001).
48. Longnecker MP. Alcoholic beverage consumption in relation to risk of breast cancer: meta-analysis and review. Cancer Causes Control 5(1), 73-82 (1994).
49. Hamajima N, Hirose K, Tajima K et al. Alcohol, tobacco and breast cancer: collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br. J. Cancer 87(11), 1234-1245 (2002).
50. Young TB. A case-control study of breast cancer and alcohol consumption habits. Cancer 64(2), 552-558 (1989).
51. Ginsburg ES. Estrogen, alcohol and breast cancer risk. J. Steroid Biochem. Mol. Biol. 69(1-6), 299-306 (1999).
52. Park SK, Yoo KY, Lee SJ et al. Alcohol consumption, glutathione-S-transferase M1 and T1 genetic polymorphisms and breast cancer risk. Pharmacogenetics 10(4), 301-309 (2000).
53. Smith-Warner SA, Spiegelman D, Yaun SS et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 279(7), 535-540 (1998).
54. Baron JA. Smoking and estrogen-related disease. Am. J. Epidemiol. 11 9(1), 9-22 (1984).
55. Morabia A, Bernstein M, Heritier S, Khatchatrian N. Relation of breast cancer with passive and active exposure to tobacco smoke. Am. J. Epidemiol. 143(9), 918-928 (1996).
56. Welp EA, Weiderpass E, Boffetta P et al. Environmental risk factors of breast cancer. Scand. J. Work Environ. Health 24 (1), 3-7 (1998).
57. Manjer J, Malina J, Berglund G et al. Smoking associated with hormone receptor negative breast cancer. Int. J. Cancer 91 (4), 580-584 (2001).
58. Brunet JS, Ghadirian P, Rebbeck TR et al. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J. Natl Cancer Inst. 90(10), 761-766 (1998).
59. Band PR, Le ND, Fang R, Deschamps M. Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet 360(9339), 1044-1049 (2002).
60. Khuder SA, Mutgi AB, Nugent S. Smoking and breast cancer: a meta-analysis. Rev. Environ. Health 16(4), 253-261 (2001).
61. International Agency for Research on Cancer. Oral contraceptives combined. In: IARC monographs on the evaluation of carcinogenic risks to humans, volume 72. Hormonal contraception and postmenopausal hormonal therapy. International Agency for Research on Cancer, Lyon, France, 49-338 (1999).
62. International Agency for Research on Cancer. Hormonal contraceptives, progestogens only. In: IARC monographs on the evaluation of carcinogenic risks to humans, volume 72. Hormonal contraception and postmenopausal hormonal therapy. International Agency for Research on Cancer, Lyon, France, 339-397 (1999).
63. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017), 1713-1727 (1996).
64. International Agency for Research on Cancer. Postmenopausal oestrogen therapy. In: IARC monoragraphs on the evaluation of carcinogenic risks to humans, volume 72. Hormonal contraception and postmenopausal hormonal therapy. International Agency for Research on Cancer, Lyon, France, 399-530 (1999).
65. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084), 1047-1059 (1997).
66. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360(9337), 942-944 (2002).
67. International Agency for Research on Cancer. Postmenopausal oestrogen-progestogen therapy. In: IARC monographs on the evaluation of carcinogenic risks to humans, volume 72. Hormonal contraception and postmenopausal hormonal therapy. International Agency for Research on Cancer, Lyon, France, 531-564 (1999).
68. Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int. J. Cancer 72(5), 758-761 (1997).
69. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10(4), 253-260 (1999).
70. Magnusson C, Baron JA, Correia N et al. Breast cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int. J. Cancer 81(3), 339-344 (1999).
71. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl Cancer Inst. 92(4), 328-332 (2000).
72. Schairer C, Lubin J, Troisi R et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283(4), 485-491 (2000).
73. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am. J. Epidemiol. 152(10), 950-964 (2000).
74. Stahlberg C, Pedersen AT, Lynge E, Ottesen B. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet. Gynecol. Scand. 82(4), 335-344 (2003).
75. Manjer J, Malina J, Berglund G et al. Increased incidence of small and well-differentiated breast tumours in postmenopausal women following hormone-replacement therapy. Int. J. Cancer 92(6), 919-922 (2001).
76. Bonnier P, Bessenay F, Sasco AJ et al. Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int. J. Cancer 79(3), 278-282 (1998).
77. Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol. 3(5), 303-311 (2002).
78. Petitti DB. Hormone replacement therapy for prevention: more evidence, more pessimism. JAMA 288(1), 99-101 (2002).
79. Grady D, Herrington D, Bittner V et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 288(1), 49-57 (2002).
80. Holley S, Furberg C, Barrett-Connor E et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 288(1), 58-66 (2002).
81. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321-333 (2002).
82. Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 13(9), 847-854 (2002).
83. Tokunaga M, Land CE, Yamamoto T et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1980. Radiat. Res. 112(2), 243-272 (1987).
84. Boice JDJ, Preston D, Davis FG, Monson RR. Frequent chest x-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Radiat. Res. 125(2), 214-222 (1991).
85. Little MP, Boice JDJ. Comparison of breast cancer incidence in the Massachusetts tuberculosis fluoroscopy cohort and in the Japanese atomic bomb survivors. Radiat. Res. 151(2), 218-224 (1999).
86. Dosemeci M, Blair A. Occupational cancer mortality among women employed in the telephone industry. J. Occup. Environ. Med. 36(11), 1204-1209 (1994).
87. Coogan PF, Clapp RW, Newcomb PA et al. Occupational exposure to 60-hertz magnetic fields and risk of breast cancer in women. Epidemiology 7(5), 459-464 (1996).
88. Feychting M, Forssen U, Rutqvist LE, Ahlbom A. Magnetic fields and breast cancer in Swedish adults residing near high-voltage power lines. Epidemiology 9(4), 392-397 (1998).
89. Cantor KP, Stewart PA, Brinton LA, Dosemeci M. Occupational exposures and female breast cancer mortality in the United States. J. Occup. Environ. Med. 37(3), 336-348 (1995).
90. Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CWJ. Occupation and breast cancer mortality in a prospective cohort of US women. Am. J. Epidemiol. 148(2), 191-197 (1998).
91. Petralia SA, Vena JE, Freudenheim JL et al. Breast cancer risk and lifetime occupational history: employment in professional and managerial occupations. Occup. Environ. Med. 55(1), 43-48 (1998).
92. Davis DL, Bradlow HL, Wolff M et al. Medical hypothesis: xenoestrogens as preventable causes of breast cancer. Environ. Health. Perspect. 101(5), 372-377 (1993).
93. Wolff MS, Toniolo PG, Lee EW, Rivera M, Dubin N. Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst. 85 (8), 648-652 (1993).
94. Dewailly E, Dodin S, Verreault R et al. High organochlorine body burden in women with estrogen receptor-positive breast cancer. J. Natl Cancer Inst. 86(3), 232-234 (1994).
95. Krieger N, Wolff MS, Hiatt RA et al. Breast cancer and serum organochlorines: a prospective study among white, black and Asian women. J. Natl Cancer Inst. 86(8), 589-599 (1994).
96. Hunter DJ, Hankinson SE, Laden F et al. Plasma organochlorine levels and the risk of breast cancer. N. Engl. J. Med. 337(18), 1253-1258 (1997).
97. Lopez-Carrillo L, Blair A, Lopez-Cervantes M et al. Dichlorodiphenyltrichloroethane serum levels and breast cancer risk: a case-control study from Mexico. Cancer Res. 57(17), 3728-3732 (1997).
98. van't Veer P, Lobbezoo IE, Martin-Moreno JM et al. DDT (dicophane) and postmenopausal breast cancer in Europe: case-control study. Br. Med. J. 315(7100), 81-85 (1997).
99. Wolff MS, Zeleniuch-Jacquotte A, Dubin N, Toniolo P. Risk of breast cancer and organochlorine exposure. Cancer Epidemiol. Biomarkers Prev. 9(3), 271-277 (2000).
100. Zheng T, Holford TR, Mayne ST et al. Risk of female breast cancer associated with serum polychlorinated biphenyls and 1,1-dichloro-2,2′-bis(p-chlorophenyl)ethylene. Cancer Epidemiol. Biomarkers Prev. 9 (2), 167-174 (2000).
101. Laden F, Hankinson SE, Wolff MS et al. Plasma organochlorine levels and the risk of breast cancer: an extended follow-up in the Nurses' Health Study. Int. J. Cancer 91(4), 568-574 (2001).
102. Aronson KJ, Miller AB, Woolcott CG et al. Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 9(1), 55-63 (2000).
103. Warner M, Eskenazi B, Mocarelli P et al. Serum dioxin concentrations and breast cancer risk in the Seveso Women's Health Study. Environ. Health Perspect. 110(7), 625-628 (2002).
104. Høyer A-P, Grandjean P, Jorgensen T, Brock JW, Hartvig HB. Organochlorine exposure and risk of breast cancer. Lancet 352(9143), 1816-1820 (1998).
105. Høyer AP, Jorgensen T, Brock JW, Grandjean P. Organochlorine exposure and breast cancer survival. J. Clin. Epidemiol. 53(3), 323-330 (2000).
106. Demers A, Ayotte P, Brisson J et al. Risk and aggressiveness of breast cancer in relation to plasma organochlorine concentrations. Cancer Epidemiol. Biomarkers Prev. 9(2), 161-166 (2000).
107. Laden F, Ishibe N, Hankinson SE et al. Polychlorinated biphenyls, cytochrome P450 1A1 and breast cancer risk in the Nurses' Health Study. Cancer Epidemiol. Biomarkers Prev. 11(12), 1560-1565 (2002).
108. Safe SH. Xenoestrogens and breast cancer. N. Engl. J. Med. 337(18), 1303-1304 (1997).
109. Musgrave MA, Aronson KJ, Narod S et al. Breast cancer and organochlorines: a marker for susceptibility? Surg. Oncol. 7(1-2), 1-4 (1998).
110. Snedeker SM. Pesticides and breast cancer risk: a review of DDT, DDE and dieldrin. Environ. Health Perspect. 109(Suppl. 1), 35-47 (2001).
111. Charlier C, Albert A, Herman P et al. Breast cancer and serum organochlorine residues. Occup. Environ. Med. 60(5), 348-351 (2003).
112. Brophy JT, Keith MM, Gorey KM et al. Occupational histories of cancer patients in a Canadian cancer treatment center and the generated hypothesis regarding breast cancer and farming. Int. J. Occup. Environ. Health 8(4), 346-353 (2002).
113. Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology 12(1), 74-77 (2001).
114. Davis S, Mirick DK, Stevens RG. Night shift work, light at night and risk of breast cancer. J. Natl Cancer Inst. 93 (20), 1557-1562 (2001).
115. Schernhammer ES, Laden F, Speizer FE et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J. Natl Cancer Inst. 93(20), 1563-1568 (2001).
116. Goldberg MS, Labreche F. Occupational risk factors for female breast cancer: a review. Occup. Environ. Med. 53(3), 145-156 (1996).
117. Dion AS, Girardi AJ, Williams CC, Pomenti AA. Serologic responses to murine mammary tumor virus (MuMTV) in MuMTV-exposed laboratory personnel. J. Natl Cancer Inst. 76(4), 611-619 (1986).
118. Stewart TH, Sage RD, Stewart AF, Cameron DW. Breast cancer incidence highest in the range of one species of house mouse, Mus domesticus. Br. J. Cancer 82(2), 446-451 (2000).
119. Glaser SL, Ambinder RF, DiGiuseppe JA, Horn-Ross PL, Hsu JL. Absence of Epstein-Barr virus EBER-1 transcripts in an epidemiologically diverse group of breast cancers. Int. J. Cancer 75(4), 555-558 (1998).
120. Herrmann K, Niedobitek G. Lack of evidence for an association of Epstein-Barr virus infection with breast carcinoma. Breast Cancer Res. 5(1), R13-R17 (2002).
121. Easton DF, Narod SA, Ford D, Steel M. The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium. Lancet 344(8924), 761 (1994).
122. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559), 789-792 (1995).
123. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 56(1), 265-271(1995).
124. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62(3), 676-689 (1998).
125. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br. J. Cancer 83(10), 1301-1308 (2000).
126. Warner E, Foulkes W, Goodwin P et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J. Natl Cancer Inst. 91(14), 1241-1247 (1999).
127. Thorlacius S, Sigurdsson S, Bjarnadottir H et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am. J. Hum. Genet. 60(5), 1079-1084 (1997).
128. Sobol H, Stoppa-Lyonnet D. Prédisposition génétique aux cancers du sein et de l'ovaire: généralités et aspects cliniques. In: Risques héréditaires de cancers du sein et de l'ovaire. Quelle prise en charge ? Les Editions INSERM, Paris, France, 81-104 (1998).
129. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer: analyses of cohort of twins from Sweden, Denmark and Finland. N. Engl. J. Med. 343(2), 78-85 (2000).
130. Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 68(3), 700-710 (2001).
131. Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nature Genet. 26(4), 411-414 (2000).
132. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nature Genet. 31(1), 33-36 (2002).
133. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358 1389-1399 (2001).
134. Narod SA, Goldgar D, Cannon-Albright L et al. Risk modifiers in carriers of BRCA1 mutations. Int. J. Cancer 64(6), 394-398 (1995).
135. Narod SA, Risch H, Moslehi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N. Engl. J. Med. 339(7), 424-428 (1998).
136. Jernstrom H, Lerman C, Ghadirian P et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354(9193), 1846-1850 (1999).
137. Becher H, Schmidt S, Chang-Claude J. Reproductive factors and familial predisposition for breast cancer by age 50 years. A case-control family study for assessing main effects and possible gene-environment interaction. Int. J. Epidemiol. 32(1), 38-48 (2003).
138. Rebbeck TR, Levin AM, Eisen A et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl Cancer Inst. 91(17), 1475-1479 (1999).
139. Narod SA, Dube MP, Klijn J et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl Cancer Inst. 94(23), 1773-1779 (2002).
140. Siiteri PK. Adipose tissue as a source of hormones. Am. J. Clin. Nutr. 45 (Suppl. 1), 277-282 (1987).
141. Nandi S, Guzman RC, Yang J. Hormones and mammary carcinogenesis in mice, rats and humans: a unifying hypothesis. Proc. Natl Acad. Sci. USA 92(9), 3650-3657 (1995).
142. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. Epidemiol. Rep. 15(1), 17-35 (1993).
143. Key TJ. Serum oestradiol and breast cancer risk. Endocr. Relat. Cancer 6(2), 175-180 (1999).
144. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol. Rev. 15(1), 48-65 (1993).
145. Hankinson SE, Willett WC, Manson JE et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl Cancer Inst. 90(17), 1292-1299 (1998).
146. la Marca A, Morgante G, Paglia T et al. Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil. Steril. 72(6), 985-989 (1999).
147. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr. Rev. 20(4), 535-582 (1999).
148. Kaaks R. Nutrition, hormones and breast cancer: is insulin the missing link? Cancer Causes Control 7(6), 605-625 (1996).
149. Stoll BA. Breast cancer: the obesity connection. Br. J. Cancer 69(5), 799-801 (1994).
150. Bruning PF, Bonfrer JM, Van Noord PA et al. Insulin resistance and breast cancer risk. Int. J. Cancer 52(4), 511-516 (1992).
151. Del Giudice ME, Fantus IG, Ezzat S et al. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res. Treat. 47(2), 111-120 (1998).
152. Kaaks R, Lundin E, Manjer J et al. Prospective study of IGF-I, IGF-binding proteins and breast cancer risk in northern and southern Sweden. Cancer Causes Control 13(4), 307-316 (2002).
153. Muti P, Quattrin T, Grant BJ et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol. Biomarkers Prev. 11(11), 1361-1368 (2002).
154. Ursin G, Longnecker MP, Haile RW, Greenland S. A meta-analysis of body mass index and risk of premenopausal breast cancer. Epidemiology 6(2), 137-141 (1995).
155. Secreto G, Zumoff B. Abnormal production of androgens in women with breast cancer. AntiCancer Res. 14(5B), 2113-2117 (1994).
156. Thomas HV, Key TJ, Allen DS et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br. J. Cancer 75 (7), 1075-1079 (1997).
157. Helzlsouer KJ, Alberg AJ, Bush TL et al. A prospective study of endogenous hormones and breast cancer. Cancer Detect. Prev. 18(2), 79-85 (1994).
158. Rosenberg CR, Pasternack BS, Shore RE, Koenig KL, Toniolo PG. Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am. J. Epidemiol. 140(6), 518-525 (1994).
159. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19(1), 1-27 (1998).
160. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 45(6), 2900-2906 (1985).
161. Jefcoate CR, Liehr JG, Santen RJ et al. Tissue-specific synthesis and oxidative metabolism of estrogens. J. Natl Cancer Inst. Monograph 27, 95-112 (2000).
162. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Ann. Rev. Pharmacol. Toxicol. 36, 203-232 (1996).
163. Cavalieri EL, Stack DE, Devanesan PD et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl Acad. Sci. USA 94(20), 10937-10942 (1997).
164. Ball P, Knuppen R. Catecholoestrogens (2-and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. Acta Endocrinol. Suppl. (Copenhagen) 232, 1-127 (1980).
165. Martucci CP, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther. 57(2-3), 237-257 (1993).
166. Schneider J, Kinne D, Fracchia A et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc. Natl Acad. Sci. USA 79(9), 3047-3051 (1982).
167. Fishman J, Schneider J, Hershcope RJ, Bradlow HL. Increased estrogen-16α-hydroxylase activity in women with breast and endometrial cancer. J. Steroid Biochem. 20(4B), 1077-1081 (1984).
168. Bradlow HL, Hershcopf RE, Fishman JF. Oestradiol 16α-hydroxylase: a risk marker for breast cancer. Cancer Surv. 5(3 , 573-583 (1986).
169. Kabat GC, Chang CJ, Sparano JA et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol. Biomarkers Prev. 6(7), 505-509 (1997).
170. Muti P, Bradlow HL, Micheli A et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 11(6), 635-640 (2000).
171. Meilahn EN, De Stavola B, Allen DS et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br. J. Cancer 78(9), 1250-1255 (1998).
172. Ursin G, London S, Stanczyk FZ et al. Urinary 2-hydroxyestrone/16 α-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J. Natl Cancer Inst. 91(12), 1067-1072 (1999).
173. Han X, Liehr JG. 8-Hydroxylation of guanine bases in kidney and liver DNA of hamsters treated with estradiol: role of free radicals in estrogen-induced carcinogenesis. Cancer Res. 54(21), 5515-5517 (1994).
174. Han X, Liehr JG. DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis 15(5), 997-1000 (1994).
175. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 21(3), 215-244 (2000).
176. Yu H, Rohan T Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst. 92(18), 1472-1489 (2000).
177. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc. Nutr Soc. 60(1), 91-106 (2001).
178. Clemmons DR, Underwood LE. Nutritional regulation of IGF-I and IGF binding proteins. Ann. Rev. Nutr. 11, 393-412 (1991).
179. Straus DS. Nutritional regulation of hormones and growth factors that control mammalian growth. FASEB J. 8(1), 6-12 (1994).
180. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 15(1), 80-101 (1994).
181. Cara JF. Insulin-like growth factors, insulin-like growth factor binding proteins and ovarian androgen production. Horm. Res. 42(1-2), 49-54 (1994).
182. Lin T, Haskell J, Vinson N, Terracio L. Direct stimulatory effects of insulin-like growth factor-I on Leydig cell steroidogenesis in primary culture. Biochem. Biophys. Res. Commun. 137(3), 950-956 (1986).
183. De Mellow JS, Handelsman DJ, Baxter RC. Short-term exposure to insulin-like growth factors stimulates testosterone production by testicular interstitial cells. Acta Endocrinol. (Copenhagen) 115(4), 483-489 (1987).
184. Plymate SR, Hoop RC, Jones RE, Matej LA. Regulation of sex hormone-binding globulin production by growth factors. Metabolism 39(9), 967-970 (1990).
185. Singh A, Hamilton-Fairley D, Koistinen R et al. Effect of insulin-like growth factor-type I (IGF-I) and insulin on the secretion of sex hormone-binding globulin and IGF-I binding protein (IBP-I) by human hepatoma cells. J. Endocrinol. 124(2), R1-R-3 (1990).
186. Erfurth EM, Hagmar LE, Saaf M, Hall K Serum levels of insulin-like growth factor I and insulin-like growth factor-binding protein 1 correlate with serum free testosterone and sex hormone binding globulin levels in healthy young and middle-aged men. Clin. Endocrinol. 44(6), 659-664(1996).
187. Pfeilschifter J, Scheidt-Nave C, Leidig-Bruckner G et al. Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50- to 80-year-old men and women. J. Clin. Endocrinol. Metab. 81(7), 2534-2540 (1996).
188. Pugeat M, Crave JC, Elmidami M et al. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J. Steroid Biochem. Mol. Biol, 40(4-6), 841-849 (1991).
189. Peyrat JP, Bonneterre J, Hecquet B et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur. J. Cancer 29A(4), 492-497 (1993).
190. Bruning PF, Van Doorn J, Bonfrer JM et al. Insulin-like growth factor-binding protein 3 is decreased in early-stage operable premenopausal breast cancer. Int. J. Cancer 62(3), 266-270 (1995).
191. Ng EH, Ji CY, Tan PH et al. Altered serum levels of insulin-like growth factor-binding proteins in breast cancer patients. Ann. Surg. Oncol. 5(2), 194-201 (1998).
192. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9(5), 570-573 (1998).
193. Petridou E, Papadiamantis Y, Markopoulos C et al. Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control 11 (5), 383-388 (2000).
194. Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113), 1393-1396 (1998).
195. Toniolo P, Bruning PF, Akhmedkhanov A et al. Serum insulin-like growth factor-I and breast cancer. Int. J. Cancer 88(5), 828-832 (2000).
196. Allen NE, Appleby PN, Davey GK, Key TJ. Hormones and diet: low insulin-like growth factor-I but normal bioavailable androgens in vegan men. Br. J. Cancer 83(1), 95-97 (2000).
197. Hall K, Hilding A, Thoren M. Determinants of circulating insulin-like growth factor-I. J. Endocrinol. Invest. 22(Suppl. 5), 48-57 (1999).
198. Hong Y, Brismar K, Hall K, Pedersen NL, de Faire U. Associations between insulin-like growth factor-I (IGF-I), IGF-binding protein-1, insulin and other metabolic measures after controlling for genetic influences: results from middle-aged and elderly monozygotic twins. J. Endocrinol. 153(2), 251-257 (1997).
199. Harrela M, Koistinen H, Kaprio J et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1 and IGFBP-3. J. Clin. Invest. 98(11), 2612-2615 (1996).
200. Verhaeghe J, Loos R, Vlietinck R et al. C-peptide, insulin-like growth factors I and II and insulin-like growth factor binding protein-1 in cord serum of twins: genetic versus environmental regulation. Am. J Obstet. Gynecol. 175(5), 1180-1188 (1996).
201. Lopez-Bermejo A, Buckway CK, Rosenfeld RG. Genetic defects of the growth hormone-insulin-like growth factor axis. Trends Endocrinol. Metab. 11(2), 39-449 (2000).
202. Jernstrom H, Deal C, Wilkin F et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol, Biomarkers Prev. 10(4), 377-384 (2001).
203. Cogan JD, Phillips JA III. Growth disorders caused by genetic defects in the growth hormone pathway. Adv. Pediatr 45, 337-361 (1998).
204. Rasmussen SK, Lautier C, Hansen L et al. Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 85(4), 1606-1610 (2000).
205. Sun G, Chagnon M, Bouchard C. A common polymorphism in the human insulin-like growth factor binding protein 3 gene. Mol. Cell Probes 14(1), 55-56 (2000).
206. Sasi R, Puebla L, Khare S, Patel YC. Polymorphism in the 5′ flanking region of the human somatostatin receptor subtype 5. Gene 214(1-2), 45-49 (1998).
207. Giordano M, Marchetti C, Chiorboli E, Bona G, Momigliano RP. Evidence for gene conversion in the generation of extensive polymorphism in the promoter of the growth hormone gene. Hum. Genet. 100(2), 249-255 (1997).
208. Chujo S, Kaji H, Takahashi Y et al. No correlation of growth hormone receptor gene mutation P561T with body height. Eur. J. Endocrinol. 134(5), 560-562 (1996).
209. Yamada Y, Stoffel M, Espinosa R III et al. Human somatostatin receptor genes: localization to human chromosomes 14, 17 and 22 and identification of simple tandem repeat polymorphisms. Genomics 15(2), 449-452 (1993).
210. Innes KE, Byers TE. Pre-eclampsia and breast cancer risk. Epidemiology 10(6), 722-732 (1999).
211. Michels KB, Trichopoulos D, Robins JM et al. Birthweight as a risk factor for breast cancer. Lancet 348(9041), 1542-1546 (1996).
212. Andersson SW, Bengtsson C, Hallberg L et al. Cancer risk in Swedish women: the relation to size at birth. Br. J. Cancer 84(9), 1193-1198 (2001).
213. Cerhan JR, Kushi LH, Olson JE et al. Twinship and risk of postmenopausal breast cancer. J. Natl Cancer Inst. 92(3), 261-265 (2000).
214. Lipworth L, Hsieh CC, Wide L et al. Maternal pregnancy hormone levels in an area with a high incidence (Boston, USA) and in an area with a low incidence (Shanghai, China) of breast cancer. Br. J. Cancer 79(1), 7-12 (1999).
215. Shu XO, Jin F, Dai Q et al. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev. 10(5), 483-488 (2001).
216. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90 (18), 1371-1388 (1998).
217. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352(9122), 98-101 (1998).
218. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352(9122), 93-97 (1998).
219. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360(9336), 817-824 (2002).
220. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 361(9354), 296-300 (2003).
221. Sasco AJ, Besson H, Bianchini E Où en eston en chimioprévention? Oncologie 4, 488-492 (2002).